(Q44054756)

English

Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).

scientific article published in July 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

hypercholesterolemia

0 references

1 reference

based on heuristic

inferred from title

intravascular ultrasound

1 reference

based on heuristic

inferred from title

familial hypercholesterolemia

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

Masunori Matsuzaki

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Katsuhiko Hiramori

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Tsutomu Imaizumi

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Akira Kitabatake

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Hitoshi Hishida

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Masanori Nomura

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Takashi Fujii

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Kenichi Fukami

9

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Takashi Honda

10

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Hiroshi Ogawa

11

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Masakazu Yamagishi

12

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

0 references

publication date

1 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Journal of the American College of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

220-227

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological and angiographic regression of coronary atherosclerosis by LDL-apheresis in a patient with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901955-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0735-1097(02)01955-1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44054756&oldid=2106078804"